Compare Novo Nordisk A/S (NVO) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rigetti Computing Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Rigetti Computing Inc trades at $14.03 (market cap $4.72B). The key difference: Novo Nordisk A/S is far larger — about 35× Rigetti Computing Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Rigetti Computing Inc for 35 Days on average.
| NVO | RGTI | |
|---|---|---|
Market Cap | $165.31B | $4.72B |
Volume | 11,432,838 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $63.98 | $56.34 |
52-Week Low | $35.29 | $12.90 |
Typical Hold Time | 116 Days | 35 Days |
Enterprise Value | $179.56B | $4.33B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
RGTI trades at $14.03, down 3.84% with bearish technical signals despite bullish oscillators. The company shows minimal revenue of $7.09M (2025) with significant losses (-$216.21M net income) and negative margins. Analyst consensus remains strong with 85.71% buy ratings and $21.67 price target, while recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC partnerships.
RGTI presents high-risk speculative potential with Wall Street optimism contrasting weak fundamentals. The stock offers substantial upside to analyst targets but faces execution risks in commercializing quantum technology amid persistent cash burn and competitive pressures from better-funded peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
